PRESS-RELEASE filed Sep 14, 2026 at 06:30 ET
Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer), for differentiating recurrent or progressive glioma from treatment-related change in adults and pediatric patients. This approval addresses a significant unmet need in a market with ~24,000 new U.S. glioma cases annually and reinforces Telix's leadership in theranostics, expanding its commercial precision diagnostics portfolio alongside Illuccix and Gozellix. The approval is a transformative catalyst for Telix, particularly as an early-stage biotech with a first-in-class commercial asset in a new indication, likely driving substantial stock appreciation.